Kyverna Therapeutics, Inc. Common Stock (KYTX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Kyverna Therapeutics, Inc. Common Stock (KYTX) is listed on Nasdaq, where it has traded since February 8, 2024.
- Listed On
- Nasdaq
- Listed Since
- February 8, 2024
- Employees
- 149
- Market Cap
- $364M
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 116 institutions reported holding KYTX, with 37.6 million shares worth $335.0 million in aggregate. The largest reported holder was Gordonmd Global Investments, with 4.2 million shares worth $37.8 million. Of the 5 largest holders listed below, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Gordonmd Global Investments | 4,244,818 | $38M | Unchanged |
| Gilead Sciences | 4,126,119 | $37M | Unchanged |
| BlackRock | 3,134,807 | $28M | Added 257.41% |
| Bain Capital Life Sciences Investors | 2,885,000 | $26M | Reduced 7.23% |
| Aigh Capital Management | 2,795,797 | $25M | Added 39.79% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is KYTX?
Kyverna Therapeutics, Inc. Common Stock (KYTX) is listed on Nasdaq, where it has traded since February 8, 2024.
Who are the largest institutional holders of KYTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of KYTX were Gordonmd Global Investments, Gilead Sciences and BlackRock.
How many institutions own KYTX?
116 institutions reported a position in KYTX for the quarter ended June 30, 2026, worth $335.0 million in total.
Did institutions buy or sell KYTX last quarter?
Of the 5 largest reported holders, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for KYTX.
Every reported institutional holder, plus insider and congressional trades in KYTX, on SentiSense.